Metabolic effects of moxonidine and other centrally acting antihypertensives.
Schachter
M
M
Department of Clinical Pharmacology and Therapeutics, Imperial College School of Medicine, St Mary's Hospital, London, UK. M.Schachter@ic.ac.uk
D000818:Animals; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000494:pharmacology*; D048909:Diabetes Complications; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D007093:Imidazoles / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D007333:Insulin Resistance; D008660:Metabolism / Q000187:drug effects*; D010080:Oxazoles / Q000008:administration & dosage / Q000627:therapeutic use; D000077769:Rilmenidine; D013564:Sympathetic Nervous System / Q000187:drug effects*; D013565:Sympatholytics / Q000494:pharmacology; D013577:Syndrome
D000959:Antihypertensive Agents; D007093:Imidazoles; D010080:Oxazoles; D013565:Sympatholytics; C043482:moxonidine; D000077769:Rilmenidine